United States

Profile: Alimera Sciences Inc (ALIM.A)

ALIM.A on American Stock Exchange

24 May 2019
Change (% chg)

$0.00 (+0.35%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Alimera Sciences, Inc. (Alimera), incorporated on June 4, 2003, is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. ILUVIEN has received marketing authorization in the United States, Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden and the United Kingdom. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.

The Company's ILUVIEN is an intravitreal implant that treats patients by delivering a constant micro-dose of the corticosteroid fluocinolone acetonide (FAc) in the eye. ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure employing a device with approximately 25-gauge needle, which allows for a self-sealing wound. ILUVIEN consists of a tiny non-bioerodable polyimide tube with a permeable membrane cap on one end and an impermeable silicone cap on the other end that is filled with approximately 190 milligrams of Fluocinolone Acetonide (FAc) in a polyvinyl alcohol matrix. Both polyimide and the polyvinyl alcohol matrix have been demonstrated to be biocompatible with ocular tissues. ILUVIEN is designed to deliver a constant micro-dose of FAc over 30 months. ILUVIEN has the potential to address other ophthalmic diseases, such as retinal vein occlusion (RVO), dry age-related macular degeneration (AMD) and wet AMD.

The Company competes with Roche Group, Regeneron, Allergan, Inc., Ophthotech Corporation, Ampio Pharmaceuticals and pSivida.

Company Address

Alimera Sciences Inc

6120 Windward Pkwy Ste 290
ALPHARETTA   GA   30005-8897
P: +1678.9905740
F: +1678.9905744

Company Web Links